54468-86-9

Basic information

• Product Name: 2-amino-N,N-dimethylbenzenesulfonamide
• Synonyms: 2-amino-N,N-dimethylbenzenesulfonamide;UKRORGSYN-BB BBV-033364;2-amino-N,N-dimethylbenzenesulfonamide(SALTDATA: FREE);2-aMino-N,N-diMethylbenzene-1-sulfonaMide
• CAS NO: 54468-86-9
• Molecular Formula: C₈H₁₂N₂O₂S
• Molecular Weight: 200.26
• Mol File: 54468-86-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 86-88 °C
• Boiling Point: 347.3±44.0 °C(Predicted)
• Appearance: /
• Density: 1.273±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: DMSO (Sparingly), Methanol (Slightly)
• PKA: -0.12±0.10(Predicted)
• CAS DataBase Reference: 2-amino-N,N-dimethylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-N,N-dimethylbenzenesulfonamide(54468-86-9)
• EPA Substance Registry System: 2-amino-N,N-dimethylbenzenesulfonamide(54468-86-9)

Safety Data

• Hazardous Substances Data: 54468-86-9(Hazardous Substances Data)

Usage

Uses

2-Amino-N,N-dimethylbenzenesulfonamide is an intermediate used to prepare LDK378 as potent and selective anaplastic lymphoma kinase inhibitor.

Upstream product

• 23530-43-0 2-(N,N-dimethylaminosulfonyl)nitrobenzene 

Downstream Products

• 501102-68-7 NSC₃₀₉₉₇₁ 

Relevant articles and documents

AXL INHIBITOR FORMULATIONS

Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a pharmaceutically accep

Compound used as ALK (anaplastic lymphoma kinase) inhibitor and application thereof

The invention discloses a compound shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, solvates or predrugs. The symptoms are defined in claim requirements. The compound shownin the formula I has good inhibiting activity on ALK (anaplastic lymphoma kinase), and can be used for preparing medicines for adjusting the activity of the ALK activity or treating the ALK-related diseases, especially nonsmall-cell lung cancer drugs. (The formula I is shown in the attached figure.).

Of tetracyclic Anaplastic lymphoma kinase inhibitors (by machine translation)

The invention belongs to the field of medical technology, in particular to general formula (I) as shown in of tetracyclic Anaplastic lymphoma kinase inhibitor, its pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 1, R 2, R 3, R 4, R 5 and A link like defined in the specification. The invention also relates to methods of preparing such compounds, pharmaceutical preparations comprising these compounds and pharmaceutical composition, the compound and, its pharmaceutically acceptable salts or stereoisomers thereof, in the preparation of the treatment and/or prevention of Anaplastic lymphoma kinase-mediated cancer diseases related to the application of the medicament. (by machine translation)